Mostrar el registro sencillo del ítem

dc.contributor.authorMukama, Trasias
dc.contributor.authorSánchez Pérez, María José 
dc.date.accessioned2022-02-02T13:08:12Z
dc.date.available2022-02-02T13:08:12Z
dc.date.issued2022-01-14
dc.identifier.citationMukama, T... [et al.]. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. Br J Cancer (2022). [https://doi.org/10.1038/s41416-021-01697-z]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/72623
dc.descriptionThe coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London-, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra,-and the Catalan Institute of OncologyICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (MR/N003284/1, MC-UU 12015/1 and MC UU_00006/1to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). Open Access funding enabled and organized by Projekt DEAL.es_ES
dc.description.abstractBACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. RESULTS: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancerfree. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9–18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. CONCLUSION: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0–9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.es_ES
dc.description.sponsorshipWorld Health Organizationes_ES
dc.description.sponsorshipDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College Londones_ES
dc.description.sponsorshipDanish Cancer Societyes_ES
dc.description.sponsorshipLigue Contre le Cancer (France)es_ES
dc.description.sponsorshipInstitut Gustave Roussy (France)es_ES
dc.description.sponsorshipMutuelle Generale de l'Education Nationale (France)es_ES
dc.description.sponsorshipInstitut National de la Sante et de la Recherche Medicale (Inserm)es_ES
dc.description.sponsorshipDeutsche Krebshilfees_ES
dc.description.sponsorshipGerman Cancer Research Center (DKFZ) (Germany)es_ES
dc.description.sponsorshipGerman Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) (Germany)es_ES
dc.description.sponsorshipFederal Ministry of Education & Research (BMBF)es_ES
dc.description.sponsorshipFondazione AIRC per la ricerca sul cancroes_ES
dc.description.sponsorshipCompagnia di San Paoloes_ES
dc.description.sponsorshipConsiglio Nazionale delle Ricerche (CNR)es_ES
dc.description.sponsorshipNetherlands Governmentes_ES
dc.description.sponsorshipWorld Cancer Research Fund International (WCRF)es_ES
dc.description.sponsorshipNetherlands Governmentes_ES
dc.description.sponsorshipHealth Research Fund (FIS)-Instituto de Salud Carlos III (ISCIII) (Spain)es_ES
dc.description.sponsorshipJunta de Andaluciaes_ES
dc.description.sponsorshipRegional Government of Asturias (Spain)es_ES
dc.description.sponsorshipRegional Government of Basque Country (Spain)es_ES
dc.description.sponsorshipRegional Government of Murcia (Spain)es_ES
dc.description.sponsorshipRegional Government of Navarra (Spain)es_ES
dc.description.sponsorshipCatalan Institute of OncologyICO (Spain)es_ES
dc.description.sponsorshipSwedish Cancer Societyes_ES
dc.description.sponsorshipSwedish Research Counciles_ES
dc.description.sponsorshipCounty Council of Skane (Sweden)es_ES
dc.description.sponsorshipCounty Council of Vasterbotten (Sweden)es_ES
dc.description.sponsorshipCancer Research UK C864/A14136 C8221/A29017es_ES
dc.description.sponsorshipUK Research & Innovation (UKRI)es_ES
dc.description.sponsorshipMedical Research Council UK (MRC) MR/N003284/1 MC-UU 12015/1 MC UU_00006/1 MR/M012190/1es_ES
dc.description.sponsorshipProjekt DEALes_ES
dc.language.isoenges_ES
dc.publisherNaturees_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleProspective evaluation of 92 serum protein biomarkers for early detection of ovarian canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1038/s41416-021-01697-z
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España